title: E-selectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells.
abstract: Increased neutrophil or HL60 cell adhesion to Rickettsia rickettsii-infected endothelial cells (ECs) was observed at 6 to 8 hours after the initiation of infection, diminishing by 24 hours. Similar increases were observed using formaldehyde-fixed neutrophils. Cellular association and likely the intracellular presence of rickettsiae was required for enhanced neutrophil adhesion, because culture medium conditioned by infected cells or rickettsiae rendered noninfective by pretreatment with tetracycline were ineffective at inducing neutrophil adhesion. Increases in neutrophil adhesion caused by infection were blocked by pretreatment of ECs with cycloheximide, suggesting the involvement of new protein synthesis in the cells' response. Flow cytometric analysis of infected cells showed increases in cell surface expression of E-selectin compared with uninfected control cells. Furthermore, incubation of 6- to 8-hour infected cells with a blocking monoclonal antibody against E-selectin (BB11) inhibited neutrophil adhesion an average of 61%. These results suggest the involvement of E-selectin in neutrophil adhesion to infected ECs occurring early in the course of the infection process. EC-initiated recruitment of neutrophil adhesion during rickettsiae infection could contribute to the pathologic changes associated with Rocky Mountain Spotted Fever.
authors.affiliation: Department of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642.
authors.forename: L A
authors.initials: LA
authors.lastname: Sporn
authors.forename: S O
authors.initials: SO
authors.lastname: Lawrence
authors.forename: D J
authors.initials: DJ
authors.lastname: Silverman
authors.forename: V J
authors.initials: VJ
authors.lastname: Marder
mesh_terms: D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology*; D015815:Cell Adhesion Molecules / Q000032:analysis / Q000096:biosynthesis / Q000502:physiology*; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D019040:E-Selectin; D004730:Endothelium, Vascular / Q000187:drug effects / Q000382:microbiology / Q000502:physiology*; D005434:Flow Cytometry; D005557:Formaldehyde / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D015473:Leukemia, Promyelocytic, Acute; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D012284:Rickettsia rickettsii / Q000502:physiology*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014471:Umbilical Veins; D014709:Vero Cells
chemical_list: D015815:Cell Adhesion Molecules; D019040:E-Selectin; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D005557:Formaldehyde; D003513:Cycloheximide